CSTONE-PHARMACEUTICALS
30.9.2020 05:24:04 CEST | Business Wire | Press release
CStone Pharmaceuticals (“CStone ”, HKEX: 2616)] and Pfizer Investment Co. Ltd. ("Pfizer Investment ") and Pfizer Corporation Hong Kong Limited ("Pfizer Hong Kong ") (both of which are subsidiaries of Pfizer Inc. (NYSE: PFE)) announced today the formation of a strategic collaboration that encompasses a $200 million equity investment by Pfizer Hong Kong in CStone, collaboration between CStone and Pfizer Investment for the development and commercialization of CStone’s sugemalimab (CS1001, PD-L1 antibody) in mainland China, and a framework between CStone and Pfizer Investment to bring additional oncology assets to the Greater China market.
This collaboration provides financing to support CStone’s development of sugemalimab, a potential best-in-class PD-L1 antibody that is being developed for high-incidence cancer indications in China, including lung, gastric and esophageal cancers, among others. Pfizer will in-license and exclusively lead commercialization of sugemalimab in China, harnessing its industry-leading capabilities to help doctors and patients across a far wider range of regions gain greater access to this treatment. The collaboration positions CStone and Pfizer to develop and commercialize additional oncology assets for the Greater China market.
“Pfizer’s investment in CStone is a statement of its confidence in the potential of our anti-PD-L1 treatment and recognition of our research and development capabilities,” said Frank Jiang, M.D., Ph.D., Chairman and Chief Executive Officer of CStone. “By joining forces with Pfizer and leveraging its commercialization infrastructure, we will ensure that patients across a vastly expanded number of markets in China have quicker access to our highly differentiated PD-L1 treatment. In addition, we have advanced our transformation into a full-fledged biopharmaceutical company by forging a collaboration that will enable us to accelerate development and commercialization of globally innovative therapies for Chinese patients.”
“Our company has an extensive and proud history of bringing innovative medicines to patients in China,” said Pierre Gaudreault, Acting President of Pfizer Biopharmaceuticals Group China. “This collaboration with CStone builds on that history by helping to develop a potential best-in-class PD-L1 treatment that we can commercialize upon approval. It also fosters our collaboration with a partner that has exceptional clinical development capabilities that can help us meet the clear need for novel oncology treatments in China.”
Key Components and Financial Terms of the Collaboration
- Pfizer obtains exclusive commercialization rights to sugemalimab in mainland China, while CStone continues to lead clinical development and regulatory strategy for five selected indications.
- CStone is entitled to receive up to $280 million in milestone payments for sugemalimab and additional tiered royalties.
- CStone retains all development and commercialization rights to sugemalimab outside mainland China.
- Pfizer will invest $200 million, consisting of 115,928,803 CStone shares at a price of US$1.725 per share (approximately HK$13.37 per share). As a result of its equity investment, Pfizer will hold a 9.90 percent stake in CStone.
- CStone and Pfizer will together select late-stage (post proof-of-concept) oncology assets for co-development in the Greater China market. These assets may come either from Pfizer’s pipeline or through joint in-licensing.
- CStone and Pfizer may pursue on a selected basis joint in-licensing arrangements for additional oncology assets for the Greater China market.
The transaction has received the necessary internal approvals of both companies. Closing is not subject to approval by CStone’s shareholders.
Goldman Sachs & Co. LLC is acting as financial advisor to CStone, and Cooley LLP served as legal advisor. Clifford Chance LLP served as Pfizer’s legal advisor.
Investor Presentation Information
CStone will host a live webcast at 11:00am (Hong Kong time) on September 30th , 2020. Please find the access information as below.
All other regions: https://event.webcasts.com/starthere.jsp?ei=1380037&tp_key=735ccdf3e4
Mainland China: https://event.gmwebcasts.cn/starthere.jsp?ei=1380037&tp_key=735ccdf3e4
Password (case sensitive): CStone
About Sugemalimab
Sugemalimab is an investigational anti-PD-L1 monoclonal antibody discovered by CStone. Authorized by a company based in the U.S., Ligand Pharmaceuticals Inc. (NASDAQ: LGND), sugemalimab is developed using the OmniRat® transgenic animal platform, which can generate fully human antibodies in one stop. As a fully human, full-length anti-PD-L1 monoclonal antibody, sugemalimab mirrors the natural G-type immunoglobulin 4 (“IgG4”) human antibody, which may reduce the risk of immunogenicity and toxicities in patients, a potentially unique advantage over similar drugs.
Sugemalimab has completed a Phase I dose-escalation study in China. During Phase 1a and 1b stages of the study, sugemalimab showed antitumor activity in multiple tumor types and was well-tolerated.
Currently, sugemalimab is being investigated in a number of ongoing clinical trials. In addition to a Phase I bridging study in the U.S., the clinical programs in China include one multi-arm Phase Ib study for several tumor types, one Phase II registrational study for lymphoma, and four Phase III registrational studies, respectively, for stage III/IV non-small cell lung cancer, gastric cancer, and esophageal cancer.
About CStone
CStone is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established at the end of 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. With a strategic emphasis on immuno-oncology combination therapies, the Company has built an oncology-focused pipeline of 15 drug candidates, including five late-stage candidates at pivotal trials or registration stages. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone’s vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide. For more information about CStone, please visit: www.cstonepharma.com .
About Pfizer: Breakthroughs and innovations to change the lives of patients
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medical and health products (including innovative drugs and vaccines) for people. Every day, Pfizer colleagues from the developed and emerging markets work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, Pfizer has worked to make a difference for all who rely on us. For more information, please visit www.pfizer.com.cn .
Forward-looking Statement
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929006175/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa16.11.2026 22:30:00 CET | Press release
European Commission approval based on data from Phase 3 STOP-HS1 and STOP-HS2, which showed that Povofortay® (povorcitinib) met the primary endpoint at Week 12 and delivered clinically meaningful, durable responses through Week 54 and was well tolerated 1,2 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Povofortay® (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa (HS). “The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease,” 2,3 said Bill Meury, Chief Executive Officer, Incyte."As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.” The approval is based on res
Moody’s Names Timothy Bhatt as Chief Information Officer16.11.2026 22:00:00 CET | Press release
Bhatt to lead enterprise technology strategy, AI deployment, and cyber and information security in Executive Leadership Team role Moody’s Corporation (NYSE: MCO) announced today that it has named Tim Bhatt to the newly created role of Chief Information Officer (CIO), effective December 7th, and that he will join the company’s Executive Leadership Team. Mr. Bhatt, who has served as Chief Technology Officer (CTO) of Moody’s Ratings since 2018, will also continue in that role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116893391/en/ Timothy Bhatt, Chief Information Officer, Moody's As CIO, Mr. Bhatt will lead Moody’s enterprise technology strategy, AI enablement, and information security, with responsibility for the company’s technology services and operations and cybersecurity teams. He will further modernize how Moody’s operates, bringing together human expertise, trusted data and AI agents to reimagine enterprise work
Lattice Extends Space Heritage with On-Orbit Milestone in TESAT Optical Communication Terminals16.11.2026 22:00:00 CET | Press release
Radiation-resilient Lattice Nexus FPGAs have operated as specified in TESAT optical communication terminals since 2025 Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that its low power, radiation-resilient Lattice Nexus™ FPGAs have surpassed one year of on-orbit operation in TESAT optical communication terminals. Since launch, the FPGAs have delivered consistent performance in the demanding application of space-based laser communication at 10 Gbps, adding to Lattice’s space heritage of thousands of FPGAs launched to date. TESAT has flown optical communication terminals on GEO and LEO missions for more than a decade, supplying broadband constellations and institutional programs. For the redesign of its terminal electronics, Lattice Nexus FPGAs addressed TESAT’s requirements for radiation tolerance, low power, and board footprint. Built on 28 nm fully depleted silicon-on-insulator (FD-SOI) process technology, the Nexus platf
New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 18:00:00 CET | Press release
New Survey of More Than 4,000 Players Finds 78% Play More During the Holidays and 82.5% Would Watch a Rewarded Ad in Exchange for a Bonus Offer Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an aud
The Rock-It Company Opens New Regional Office in Nashville16.11.2026 17:00:00 CET | Press release
The expansion demonstrates The Rock-It Company’s dedication to the iconic live music market and opens a new centralized hub that connects live events and luxury goods in a fast-growing region. The Rock-It Company, a global leader in live events and luxury goods logistics, announced the opening of a new regional office in Nashville, Tennessee, reinforcing its presence in one of the world's most important live music and cultural markets. The Nashville office brings together the full Rock-It platform with dedicated offices for Rock-It Cargo, Rock-It Sports, CARS by Rock-It and DIETL by Rock-It, serving as a regional hub for the company's broader portfolio of specialty logistics offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116286387/en/ The Rock-It Company office in Nashville, Tennessee “Nashville has been a central part of our business for decades, and we see tremendous opportunity to continue building on that f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
